This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.
5 Biotech Stocks Set to Trump Estimates This Earnings Season
by Zacks Equity Research
Total earnings for the medical sector are up 16.9% from the same period last year on 8.5% higher revenues so far.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion's (ALXN) Q4 results are likely to driven by Soliris' performance.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Teva's (TEVA) Generics segment sales are likely to be weak due to increased pricing erosion while loss of exclusivity of key drugs like Copaxone will hurt sales in the Specialty segment.
Is a Beat in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might lead the company to an earnings beat in Q4.
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.
Will Bristol-Myers' (BMY) Q4 Earnings Exceed Expectations?
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo is likely to play an instrumental role in driving fourth-quarter 2017 results.
What's in the Cards for GW Pharma (GWPH) in Q1 Earnings?
by Zacks Equity Research
GW Pharma (GWPH) will report fiscal first-quarter results next week. Investors focus is expected to be on the Epidiolex commercialization plan.
Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.
Will Amgen (AMGN) Benefit From Growth Drugs in Q4 Earnings?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, AbbVie and Merck
What's in the Cards for Varian Medical (VAR) in Q1 Earnings?
by Zacks Equity Research
Varian Medical's (VAR) lackluster performance in Halcyon platform and disappointing financials are likely to dampen results in Q1.
What's in the Cards for Biogen (BIIB) This Earnings Season?
by Zacks Equity Research
On the Q4 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise, and Spinraza's performance.
Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season?
by Arpita Dutt
Here is a look at four large-cap pharma and biotech stocks including Merck (MRK) that could surpass earnings expectations in the fourth quarter.
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex
Can Biotech Keep Last Year's Momentum Alive in 2018?
by Zacks Equity Research
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Omeros Inks Agreement With FDA for OMS721 Phase III Trial
by Zacks Equity Research
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?
by Zacks Equity Research
Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.
Alexion's (ALXN) Soliris Label Expansion Approved in Japan
by Zacks Equity Research
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
Achillion's Renal Disease Candidate Gets Orphan Drug Status
by Zacks Equity Research
Achillion Pharmaceuticals' (ACHN) factor D inhibitor, ACH-4471, gets orphan drug designation for treating C3G, a renal disease.
Alexion (ALXN) in Focus: Stock Moves 7.2% Higher
by Zacks Equity Research
Alexion (ALXN) shares rose more than 7% in the last trading session, amid huge volumes.
4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018
by Zacks Equity Research
Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.
Alexion (ALXN) Down 14.6% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Alexion (ALXN) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotechs Trading Lower in Q4 on Macro Uncertainty, Tepid Q3
by Zacks Equity Research
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.